(562) Donor-Derived Cell-Free DNA in Heart Transplant Recipients Bridged with Left Ventricular Assist Device

PurposeLeft Ventricular Assist Device (LVAD) as a bridge to heart transplantation (BTT) has been described risk factor for post-heart (HT) sensitization and rejection. Donor-derived cell-free-DNA (dd-cfDNA) test is noninvasive method surveillance of allograft injury. We sought characterize dd-cfDNA in LVAD-BTT recipients compared non-LVAD patients its impact on post-HT outcomes.MethodsPatients who underwent HT our institution between January 2019 July 2022 had at least one result were included the analysis. Patients grouped based presence pre-HT durable LVAD. Dd-cfDNA was considered positive if ≥0.12%. Samples reported <0.12% analyzed 0.11% purpose this analysis.ResultsA total 225 identified. 66 159 included. The median age 56 years similar groups. majority (73%) males. 45 (68%) supported HeartMate 3 number samples per patient both groups (8 [6,10] vs. 8 [4.5,9]) found 67% 64% non-LVAD, respectively. levels (0.119 [0.110, 0.156] 0.117 0.186]; p=0.65). Similarly, there no significant difference incidence cellular antibody-mediated rejection.ConclusionPatients with LVAD prior undergoing not Left outcomes. A